ES2166102T3 - Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace. - Google Patents
Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace.Info
- Publication number
- ES2166102T3 ES2166102T3 ES97946246T ES97946246T ES2166102T3 ES 2166102 T3 ES2166102 T3 ES 2166102T3 ES 97946246 T ES97946246 T ES 97946246T ES 97946246 T ES97946246 T ES 97946246T ES 2166102 T3 ES2166102 T3 ES 2166102T3
- Authority
- ES
- Spain
- Prior art keywords
- inflammation
- disease
- environment
- occupational
- heteroarilo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 title abstract 3
- 150000007513 acids Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 title 1
- 239000011159 matrix material Substances 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 abstract 5
- 230000004054 inflammatory process Effects 0.000 abstract 5
- 208000028571 Occupational disease Diseases 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
- 208000025494 Aortic disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000013382 Gelatinases Human genes 0.000 abstract 1
- 108010026132 Gelatinases Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010054094 Tumour necrosis Diseases 0.000 abstract 1
- 208000025865 Ulcer Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 201000001474 proteinuria Diseases 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 230000008736 traumatic injury Effects 0.000 abstract 1
- 230000036269 ulceration Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/42—Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
- C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
- C07D273/06—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Virology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE AL DESCUBRIMIENTO DE NUEVOS INHIBIDORES NO PEPTIDICOS, DE BAJO PESO MOLECULAR, DE METALOPROTEINASAS MATRICIALES (POR EJEMPLO, GELATINASAS, ESTROMELISINAS Y COLAGENASAS) Y DE LA ENZIMA DE CONVERSION DEL FNT - AL (ECANT, ENZIMA DE CONVERSION DEL FACTOR AL DE LA NECROSIS TUMORAL), QUE SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES EN LAS QUE ESTAN IMPLICADAS ESTAS ENZIMAS, TALES COMO LA ARTRITIS, EL CRECIMIENTO Y METASTASIS TUMORALES, LA ANGIOGENESIS, ULCERACION TISULAR, CURACION EN FALSO DE HERIDAS, ENFERMEDAD PERIODONTAL, ENFERMEDAD OSEA, PROTEINURIA, ENFERMEDAD AORTICA ANEURISMICA, PERDIDA DEGENERATIVA DE CARTILAGO TRAS LESION TRAUMATICA EN UNA ARTICULACION, ENFERMEDADES DE DESMIELINIZACION DEL SISTEMA NERVIOSO, RECHAZO DE INJERTOS, CAQUEXIA, ANOREXIA, INFLAMACION, FIEBRE, INSULINO - RESISTENCIA, CHOQUE SEPTICO, INSUFICIENCIA CARDIACA CONGESTIVA, ENFERMEDAD INFLAMATORIA DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDAD INFLAMATORIA DEL INTESTINO, INFECCION POR VIH, DEGENERACION MACULAR RELACIONADA CON EL ENVEJECIMIENTO, RETINOPATIA DIABETICA, VITREORRETINOPATIA DIABETICA, VITREORRETINOPATIA PROLIFERATIVA, RETINOPATIA POR PREMADUREZ, INFLAMACION OCULAR, QUERATOCONO, SINDROME DE SJOGREN, MIOPIA, TUMORES OCULARES, ANGIOGENESIS/NEOVASCULARIZACION OCULAR. LOS ACIDOS ORTO - SULFONAMIDO - ARIL - HIDROXAMICOS INHIBIDORES DE LA ECANT Y DE LAS MPM (METALOPROTEINASAS MATRICIALES) DE LA PRESENTE INVENCION ESTAN REPRESENTADAS POR LA FORMULA (I) EN LA QUE LA MITAD DEL ACIDO HIDROXAMICO Y LA MITAD DEL SULFONAMIDO ESTAN FIJADAS A CARBONES ADYACENTES EN EL GRUPO A, EN DONDE: A ES FENILO O NAFTILO, OPTATIVAMENTE SUSTITUIDO POR R 1 , R 2 , R 3 Y R 4 ; Z ES ARILO, HETEROARILO, O HETEROARILO FUSIONADO A UN FENILO, EN DONDE ARILO ES FENILO O NAFTILO OPTATIVAMENTE SUSTITUIDO POR R 1 , R 2 , R 3 Y R 4 ; HETEROARILO ES UN ANILLO HETEROAROMATICO DE 5 A 6 MIEMBROS, QUE TIENE DE 1 A 3 HETEROATOMOS SELECCIONADOS INDEPENDIENTEMENTE ENTRE N, O Y S, Y OPTATIVAMENTE SUSTITUIDOS POR R1, R 2 , R 3 Y R 4 ; Y CUANDO EL HETEROARILO ESTA FUSIONADO AL FENILO, UNO O AMBOS DE LOS ANILLOS PUEDEN SER OPTATIVAMENTE SUSTITUIDOS POR R 1 , R 2 , R 3 Y R 4 ; Y R 1 , R 2 , R 3 Y R 4 , R 5, R 6 , R 7 , R 8 Y R 9 SE DESCRIBEN EN LA MEMORIA; ASI COMO LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS Y SUS ISOMEROS Y DIASTEREOMEROS OPTICOS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73263196A | 1996-10-16 | 1996-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2166102T3 true ES2166102T3 (es) | 2002-04-01 |
Family
ID=24944349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97946246T Expired - Lifetime ES2166102T3 (es) | 1996-10-16 | 1997-10-08 | Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace. |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0938471B1 (es) |
JP (1) | JP2001504809A (es) |
KR (1) | KR20000049196A (es) |
AR (1) | AR009382A1 (es) |
AT (1) | ATE210637T1 (es) |
AU (1) | AU731737B2 (es) |
BR (1) | BR9712525A (es) |
CA (1) | CA2268894A1 (es) |
DE (1) | DE69709160T2 (es) |
DK (1) | DK0938471T3 (es) |
ES (1) | ES2166102T3 (es) |
HK (1) | HK1021178A1 (es) |
HU (1) | HUP0000641A3 (es) |
IL (1) | IL129147A0 (es) |
NZ (1) | NZ335028A (es) |
PT (1) | PT938471E (es) |
TW (1) | TW410220B (es) |
WO (1) | WO1998016503A2 (es) |
ZA (1) | ZA979233B (es) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4229499A (en) | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
PL345776A1 (en) * | 1998-07-30 | 2002-01-02 | Warner Lambert Co | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
AU5647099A (en) * | 1998-09-11 | 2000-04-03 | Shionogi & Co., Ltd. | Remedal or preventive agent for congestive heart failure |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
EP1147085B1 (en) | 1999-01-27 | 2005-11-16 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
WO2000044710A2 (en) * | 1999-01-27 | 2000-08-03 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
AR035478A1 (es) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene |
US6465468B1 (en) | 1999-03-22 | 2002-10-15 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives |
GB9911071D0 (en) * | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
GB9911073D0 (en) * | 1999-05-12 | 1999-07-14 | Darwin Discovery Ltd | Hydroxamic and carboxylic acid derivatives |
PT1233958E (pt) | 1999-11-23 | 2011-09-20 | Methylgene Inc | Inibidores de histona desacetilase |
AR027943A1 (es) * | 2000-02-25 | 2003-04-16 | Wyeth Corp | Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
US6858600B2 (en) * | 2001-05-08 | 2005-02-22 | Yale University | Proteomimetic compounds and methods |
WO2003037852A1 (en) | 2001-11-01 | 2003-05-08 | Wyeth Holdings Corporation | Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors |
US20040029771A1 (en) * | 2002-02-28 | 2004-02-12 | Icagen, Inc. | Methods for treating diseases related to intraocular pressure |
US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US7199155B2 (en) | 2002-12-23 | 2007-04-03 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors |
EP1449538A1 (en) * | 2003-02-21 | 2004-08-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation |
KR100793095B1 (ko) * | 2003-10-01 | 2008-01-10 | 주식회사 프로메디텍 | Bace 저해효능을 가진 신규한 술폰 아미드 유도체 |
US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
CN1997638B (zh) | 2004-04-07 | 2011-07-06 | 默克雪兰诺有限公司 | 作为ptp1-b抑制剂的1,1'-(1,2-乙炔二基)双苯衍生物 |
FR2872159B1 (fr) * | 2004-06-28 | 2007-10-05 | Merck Sante Soc Par Actions Si | Nouveaux derives acides carboxyliques phenyliques et leur utilisation dans le traitement du diabete |
WO2007087441A2 (en) | 2006-01-25 | 2007-08-02 | Synta Pharmaceuticals Corp. | Substituted aromatic compounds for inflammation and immune-related uses |
CA2667826C (en) * | 2006-10-28 | 2013-10-08 | Methylgene Inc. | Inhibitors of histone deacetylase |
TWI415827B (zh) | 2006-12-21 | 2013-11-21 | Du Pont | 製備2-胺基-5-氰基苯甲酸衍生物之方法 |
GB0705400D0 (en) | 2007-03-21 | 2007-05-02 | Univ Aberdeen | Therapeutic compounds andm their use |
US7850453B2 (en) | 2007-08-08 | 2010-12-14 | Coll Partners Ltd. | Reshapable device for fixation at a dental site |
GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
WO2010125831A1 (en) * | 2009-05-01 | 2010-11-04 | Raqualia Pharma Inc. | Sulfamoyl benzoic acid derivatives as trpm8 antagonists |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2962649A1 (fr) | 2010-07-19 | 2012-01-20 | Conservatoire Nat Arts Et Metiers | Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
US9668844B2 (en) | 2013-11-06 | 2017-06-06 | Colldent Y.A Ltd | Device for fixation at a dental site |
TWI678354B (zh) | 2014-05-29 | 2019-12-01 | 新加坡商艾佛艾姆希農業新加坡有限公司 | 藉空氣氧化製備3-甲基-2-硝基苯甲酸之製程 |
SI3262028T1 (sl) | 2014-12-17 | 2022-02-28 | Pimco 2664 Limited | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamidne in N-(-4hidroksi-4-metil-cikloheksil)-4-(2-piridil)-benzensulfonamidne spojine in njihova terapevtska uporaba |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
WO2017117130A1 (en) | 2015-12-28 | 2017-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
EP3199534B1 (en) | 2016-02-01 | 2018-09-05 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
WO2024028654A2 (en) * | 2022-08-05 | 2024-02-08 | The Governing Council Of The University Of Toronto | Histone deacetylase inhibitors and use of the same |
CN116120261B (zh) * | 2022-11-30 | 2024-01-23 | 浙大宁波理工学院 | 一种3-[(4-磺胺哌嗪-1-基)甲基]苯甲酸类化合物的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
JPH10501806A (ja) * | 1994-06-22 | 1998-02-17 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
-
1997
- 1997-10-08 ES ES97946246T patent/ES2166102T3/es not_active Expired - Lifetime
- 1997-10-08 WO PCT/US1997/018280 patent/WO1998016503A2/en not_active Application Discontinuation
- 1997-10-08 DE DE69709160T patent/DE69709160T2/de not_active Expired - Fee Related
- 1997-10-08 AT AT97946246T patent/ATE210637T1/de not_active IP Right Cessation
- 1997-10-08 CA CA002268894A patent/CA2268894A1/en not_active Abandoned
- 1997-10-08 PT PT97946246T patent/PT938471E/pt unknown
- 1997-10-08 JP JP51844898A patent/JP2001504809A/ja not_active Ceased
- 1997-10-08 IL IL12914797A patent/IL129147A0/xx unknown
- 1997-10-08 EP EP97946246A patent/EP0938471B1/en not_active Expired - Lifetime
- 1997-10-08 HU HU0000641A patent/HUP0000641A3/hu unknown
- 1997-10-08 KR KR1019990703294A patent/KR20000049196A/ko not_active Application Discontinuation
- 1997-10-08 NZ NZ335028A patent/NZ335028A/xx unknown
- 1997-10-08 AU AU51458/98A patent/AU731737B2/en not_active Ceased
- 1997-10-08 DK DK97946246T patent/DK0938471T3/da active
- 1997-10-08 BR BR9712525-3A patent/BR9712525A/pt not_active Application Discontinuation
- 1997-10-15 TW TW086114187A patent/TW410220B/zh not_active IP Right Cessation
- 1997-10-15 AR ARP970104751A patent/AR009382A1/es not_active Application Discontinuation
- 1997-10-15 ZA ZA979233A patent/ZA979233B/xx unknown
-
2000
- 2000-01-06 HK HK00100090A patent/HK1021178A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
HUP0000641A3 (en) | 2001-02-28 |
DE69709160D1 (de) | 2002-01-24 |
KR20000049196A (ko) | 2000-07-25 |
ZA979233B (en) | 1999-04-15 |
PT938471E (pt) | 2002-05-31 |
WO1998016503A3 (en) | 1998-05-28 |
NZ335028A (en) | 2000-09-29 |
EP0938471B1 (en) | 2001-12-12 |
BR9712525A (pt) | 1999-10-19 |
JP2001504809A (ja) | 2001-04-10 |
AR009382A1 (es) | 2000-04-12 |
TW410220B (en) | 2000-11-01 |
EP0938471A1 (en) | 1999-09-01 |
HK1021178A1 (en) | 2000-06-02 |
DK0938471T3 (da) | 2002-01-28 |
AU731737B2 (en) | 2001-04-05 |
ATE210637T1 (de) | 2001-12-15 |
AU5145898A (en) | 1998-05-11 |
WO1998016503A2 (en) | 1998-04-23 |
HUP0000641A2 (hu) | 2000-10-28 |
DE69709160T2 (de) | 2002-08-14 |
CA2268894A1 (en) | 1998-04-23 |
IL129147A0 (en) | 2000-02-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2166102T3 (es) | Preparacion y utilizacion de acidos orto-sulfonamidoarilhidroxamicos como inhibidores de las metaloproteinasas matriz y los tace. | |
ES2184069T3 (es) | Acidos beta-sulfonamidohidroxamicos como inhibidores de las metaloproteinasas de la matriz y de la tace. | |
AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
BR9714350A (pt) | Preparação e uso de ácidos orto-sulfonamido heteroaril hidroxâmicos com inibidores de metaloproteinases de matriz e da tace | |
AR011101A1 (es) | Compuesto derivado de acidos arilsulfonilaminohidroxiamicos y composicion farmaceutica que lo contiene | |
ES2090065T3 (es) | Esteres de acido fosforico, procedimiento para su fabricacion y su utilizacion como agente dispersante. | |
ES536499A0 (es) | Un procedimiento para la preparacion de nuevas 2-amino-5-hidroxi-4-metilpirimidinas. | |
FI906438A (fi) | Menetelmä uusien, terapeuttisesti käyttökelpoisten A-nor-steroidi-3-karboksyylihappojohdannaisten valmistamiseksi | |
ES542321A0 (es) | Un procedimiento para la preparacion de derivados de la 2 pirimidinil-1-piperazina | |
ES2082755T3 (es) | Derivados de acido 3-desmetil-mevalonico, procedimiento para su preparacion, preparados farmaceuticos a base de estos compuestos, su utilizacion asi como productos intermedios. | |
BR9813022A (pt) | Derivados de ésteres hidroxiacéticos, seu processo de preparação e sua utilização como intermediários de sìntese | |
ES2169248T3 (es) | Compuestos aromaticos y composiciones farmaceuticas que los contienen. | |
AR009379A1 (es) | Derivados de acido piperidin-cetocarboxilico, su uso y composiciones farmaceuticas que los contienen | |
MX9200063A (es) | Derivados de acidos tetrahidrofolicos y procedimiento para su preparacion. | |
ES2032405T3 (es) | Derivados de los acidos valproico y (e)-2-valproenoico, procedimientos para su preparacion y composiciones farmaceuticas que los contienen. | |
NO20050612L (no) | Pyrrolidinderivater som oksytocinantagonister | |
PT91456A (pt) | Processo para a preparacao de derivados de naftoquinonas e de composicoes farmaceuticas que os contem | |
MX3394E (es) | Procedimiento para preparar benzofenonas | |
ES2056639T3 (es) | Procedimiento para la transformacion del acido (benzoil-3 fenil)-2 propionico-r(-) en isomero s(+). | |
EA200001101A1 (ru) | НОВЫЕ ДИГИДРОФУРО[3,4-b]ХИНОЛИН-1-ОНЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ | |
ES2031900T3 (es) | Un procedimiento para la produccion de antibioticos de eter policiclicos. | |
ES2062407T3 (es) | Compuestos de 2-hidroxi-3-fenoxipropilamino. | |
ES2017483B3 (es) | Amidas del acido diselenobis benzoico de aminas heterociclicas primarias, proceso para la produccion de las mismas, y compuestos farmaceuticos que las contienen. | |
ES2116029T3 (es) | Procedimiento para preparar derivados de piperazina opticamente activos e intermedios para prepararlos. | |
IL81503A0 (en) | N-phthalimidobenzoic acid esters,their preparation and their use as herbicides and plant-growth regulators |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 938471 Country of ref document: ES |